Translate this page to:
Dutch
In JoVE (1)
Other Publications (1)
Automatic Translation
This translation into Dutch was automatically generated.
English Version | Other Languages
Articles by Matthew L. Fowler in JoVE
JoVE General
Directe detectie van de acetaat-vormende activiteit van het enzym acetaat Kinase
Department of Genetics and Biochemistry, Clemson University
Een methode voor de bepaling van acetaat kinase activiteit is beschreven. Deze test maakt gebruik van een directe reactie voor het bepalen van enzymactiviteit en de kinetiek van acetaat kinase in de acetaat-vormende richting met verschillende fosforyl acceptoren. Bovendien kan deze methode worden gebruikt voor het testen van andere acetyl fosfaat of acetyl-CoA gebruik te maken van enzymen.
Other articles by Matthew L. Fowler on PubMed
The Anti-trypanosomal Agent Lonidamine Inhibits Trypanosoma Brucei Hexokinase 1
Glycolysis is essential to the parasitic protozoan Trypanosoma brucei. The first step in this metabolic pathway is mediated by hexokinase, an enzyme that transfers the gamma-phosphate of ATP to a hexose. The T. brucei genome (TREU927/4 GUTat10.1) encodes two hexokinases (TbHK1 and TbHK2) that are 98% identical at the amino acid level. Our previous efforts have revealed that TbHK2 is an important regulator of TbHK1 in procyclic form parasites. Here, we have found through RNAi that TbHK1 is essential to the bloodstream form parasite. Silencing the gene for 4 days reduces cellular hexokinase approximately 60% and leads to parasite death. Additionally, we have found that the recombinant enzyme is inhibited by lonidamine (IC(50)=850 microM), an anti-cancer drug that targets tumor hexokinases. This agent also inhibits HK activity from whole parasite lysate (IC(50)=965 microM). Last, lonidamine is toxic to cultured bloodstream form parasites (LD(50)=50 microM) and procyclic form parasites (LD(50)=180 microM). Interestingly, overexpression of TbHK1 protects PF parasites from lonidamine. These studies provide genetic evidence that TbHK1 is a valid therapeutic target while identifying a potential molecular target of the anti-trypanosomal agent lonidamine.
